Efficacy and safety of adjuvant ovarian suppression with Buserelin-depo in premenopausal women with hormone-positive breast cancer
https://doi.org/10.21518/2079-701X-2019-10-87-91
Abstract
Breast cancer (BC) ranks first in the morbidity pattern among women in Russia. Adjuvant endocrinotherapy is an important step in the complex treatment of premenopausal patients with hormone-positive early breast cancer. The drug ovarian suppression with GnRH-agonists have supplanted surgical castration and radiation-based treatment of the ovaries in patients with hormone-positive early breast cancer. Today, several drugs authorised for the treatment of breast cancer are used in clinical practice: goserelin, buserelin and triptorelin. Buserelin-depo is an effective method for achieving ovarian suppression. The results obtained do not differ from similar indicators obtained in using imported LHRH analogues.
About the Authors
L. K. Ovchinnikova
State Budgetary Healthcare Institution of Moscow Region «Moscow Regional Oncological Dispensary».
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Head of Oncology (breast tumours) Department No. 6, State Budgetary Healthcare Institution of Moscow Region «Moscow Regional Oncological Dispensary».
A. D. Belko
State Budgetary Healthcare Institution of Moscow Region «Moscow Regional Oncological Dispensary».
Russian Federation
Russian Federation
Physician, Oncology (breast tumours) Department No. 6, State Budgetary Healthcare Institution of Moscow Region «Moscow Regional Oncological Dispensary».
References
1. Семиглазова Т.Ю., Берлев И.В., Ульрих Е.А., Семиглазов В.В., Коробейникова Е.А., Проценко С.А., Криворотько П.В., Семиглазов В.Ф. Протективная и лечебная роль овариальной супрессии при раннем раке молочной железы. RUSSCO. Газета Российского общества клинической онкологии. 2018; выпуск 4. [Semiglazova T.Yu., Berlev I.V., Ulrich E.A., Semiglazov V.V., Korobeynikova E.A., Protsenko S.A., Krivorotko P.V., Semiglazov V.F. Protective and therapeutic role of ovarian suppression in early breast cancer. RUSSCO. Gazeta Rossiyskogo Obshchestva Klinicheskoi Onkologii. 2018; Issue 4.] (In Russ).
2. Стенина М.Б. Гормонотерапия диссеминированного рака молочной железы. Практическая онкология. 2000 июнь;2:12-18. [Stenina M.B. Endocrin therapy for disseminated breast cancer. Prakticheskaya Onkologia. June 2000;2:12-18.] (In Russ).
3. Семиглазов В.Ф., Криворотько П.Ф., Семигла зова Т.Ю., Николаев К.С., Комяков А.В., Дашян Г.А., Семиглазов В.В., Палтуев Р.М. Практические рекомендации по лечению рака молочной железы, 2017. [Semiglazov V.F., Krivorotko P.F., Semiglazova T.Yu., Nikolaev K.S., Komyakov A.V., Dashyan G.A., Semiglazov V.V., Paltuev R.M. Prac tical guidelines for the treatment of breast cancer, 2017.] (In Russ).
4. Bonnetere J. et al. Preliminary results of a large comparative multi@center clinical trial comparing the efficacy and tolerability of Arimidex (anastrozole) and Tamoxifen in postmenopausal women with advanced breast cancer. Eur J Cancer. 1999.
5. Conte C.C., Nemoto T., Rosner D. et al. Therapeutic oophorectomy in metastatic breast cancer. Cancer. 1989;64:150-153.
6. Жуков Н.В. Роль выключения функции яичников в адъювантной терапии больных раком молочной железы, позитивным по рецепторам эстрогенов. Есть ли она? Злокачественные опухоли. 2012;1:28-36. [Zhukov N.V. Role of ovarian function suppression in adjuvant treatment of patients with estrogen receptor positive breast cancer. Is there any? Zlokachestvennye Opukholi. 2012;1:28-36.] (In Russ).
7. Chia S.K., Speers C.H., D , Yfchkova Y. et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007;110:973.
8. Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet. 1896;2:104–107.
9. Bland K.I., Fuchs A., Wittliss J.L. Menopausal status as a factor in the distribution of estrogen and progestin receptors in breast cancer. 37th Annual Meeting of the Forum on Fundamental surgical Problems. Surg Forum. 1981;32:410
10. Fossati R., Confalonieri C., Torri V. et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31510 women. J Clin Oncology. 1998;16(10).
Review
For citations:
Ovchinnikova LK, Belko AD. Efficacy and safety of adjuvant ovarian suppression with Buserelin-depo in premenopausal women with hormone-positive breast cancer. Meditsinskiy sovet = Medical Council. 2019;(10):87-91. (In Russ.) https://doi.org/10.21518/2079-701X-2019-10-87-91
Views:
1285
Email this article 